blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3228313

EP3228313 - DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE [Right-click to bookmark this link]
Former [2017/41]DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE
[2019/15]
StatusNo opposition filed within time limit
Status updated on  17.07.2020
Database last updated on 01.04.2026
FormerThe patent has been granted
Status updated on  09.08.2019
FormerGrant of patent is intended
Status updated on  20.03.2019
FormerExamination is in progress
Status updated on  12.10.2018
FormerRequest for examination was made
Status updated on  13.04.2018
FormerThe application has been published
Status updated on  08.09.2017
Most recent event   Tooltip15.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 17.08.2022  [2022/33]
Applicant(s)For all designated states
Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080 / US
[2017/41]
Inventor(s)01 / Snodgrass, Ralph H.
20781 Via Corta
San Jose, CA California 95120 / US
02 / Cato, Allen E.
Cato Research, 4364 S. Alston Avenue
Durham, NC North Carolina 27713 / US
03 / Hicklin, Jack S.
Cato Research, 6480 Weathers Place, Suite 104
San Diego, CA California 92121 / US
 [2017/41]
Representative(s)Jacobi, Markus Alexander
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Eastsite One
Seckenheimer Landstraße 4
68163 Mannheim / DE
[2019/37]
Former [2017/41]Jacobi, Markus Alexander
Isenbruck Bösl Hörschler LLP
Patentanwälte
Eastsite One
Seckenheimer Landstraße 4
68163 Mannheim / DE
Application number, filing date17170079.222.01.2014
[2017/41]
Priority number, dateUS201361849191P22.01.2013         Original published format: US 201361849191 P
[2017/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3228313
Date:11.10.2017
Language:EN
[2017/41]
Type: B1 Patent specification 
No.:EP3228313
Date:11.09.2019
Language:EN
[2019/37]
Search report(s)(Supplementary) European search report - dispatched on:EP07.09.2017
ClassificationIPC:A61K31/198, A61P25/28, A61P25/24, A61P25/14, A61P25/04
[2017/41]
CPC:
A61K31/198 (EP,IL,KR,US); A61K9/0053 (IL,US); A61P25/04 (IL);
A61P25/14 (EP); A61P25/16 (EP); A61P25/24 (KR);
A61K2300/00 (IL); Y02A50/30 (EP) (-)
C-Set:
A61K31/198, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]
Former [2017/41]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DOSIERUNGSFORMEN UND THERAPEUTISCHE VERWENDUNGEN VON L-4-CHLORKYNURENIN[2017/41]
English:DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE[2019/15]
French:FORMES POSOLOGIQUES ET UTILISATIONS THÉRAPEUTIQUES DE LA L-4-CHLOROCYNURÉNINE[2017/41]
Former [2017/41]DOSAGE FORMS AND THERAPEUTIC USES L-4-CHLOROKYNURENINE
Examination procedure09.05.2017Date on which the examining division has become responsible
14.02.2018Amendment by applicant (claims and/or description)
10.04.2018Examination requested  [2018/20]
10.10.2018Despatch of a communication from the examining division (Time limit: M04)
18.02.2019Reply to a communication from the examining division
21.03.2019Communication of intention to grant the patent
31.07.2019Fee for grant paid
31.07.2019Fee for publishing/printing paid
31.07.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14743570.5  / EP2948140
Divisional application(s)EP19196366.9  / EP3598971
EP24164414.5
Opposition(s)15.06.2020No opposition filed within time limit [2020/34]
Fees paidRenewal fee
09.05.2017Renewal fee patent year 03
09.05.2017Renewal fee patent year 04
29.01.2018Renewal fee patent year 05
28.01.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.01.2014
AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
MC11.09.2019
MK11.09.2019
MT11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS12.01.2020
LU22.01.2020
[2022/33]
Former [2022/29]HU22.01.2014
AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
MC11.09.2019
MT11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS12.01.2020
LU22.01.2020
Former [2020/46]AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
MC11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS12.01.2020
LU22.01.2020
Former [2020/39]AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
MC11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS12.01.2020
Former [2020/36]AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS12.01.2020
Former [2020/27]AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
SM11.09.2019
NO11.12.2019
GR12.12.2019
IS24.02.2020
Former [2020/26]AL11.09.2019
CZ11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
RO11.09.2019
SK11.09.2019
NO11.12.2019
GR12.12.2019
IS24.02.2020
Former [2020/23]AL11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
RO11.09.2019
NO11.12.2019
GR12.12.2019
Former [2020/22]AL11.09.2019
EE11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
NO11.12.2019
GR12.12.2019
Former [2020/20]AL11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NL11.09.2019
NO11.12.2019
GR12.12.2019
Former [2020/15]AL11.09.2019
FI11.09.2019
LT11.09.2019
LV11.09.2019
NO11.12.2019
GR12.12.2019
Former [2020/12]FI11.09.2019
LT11.09.2019
LV11.09.2019
NO11.12.2019
GR12.12.2019
Former [2020/09]FI11.09.2019
LT11.09.2019
NO11.12.2019
Former [2020/08]LT11.09.2019
NO11.12.2019
Documents cited:Search[A] US2011306674  (SCHIENE KLAUS et al.)
 [A]   HUI-QIU WU ET AL: "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 390, no. 3, 1 March 2000 (2000-03-01), NL, pages 267 - 274, XP055269951, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(00)00024-8

DOI:   http://dx.doi.org/10.1016/S0014-2999(00)00024-8
 [A]   SONG-CHU LEE ET AL: "Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo", NEUROSCIENCE LETTERS, vol. 304, no. 3, 1 May 2001 (2001-05-01), IE, pages 185 - 188, XP055283122, ISSN: 0304-3940, DOI: 10.1016/S0304-3940(01)01791-8

DOI:   http://dx.doi.org/10.1016/S0304-3940(01)01791-8
 [A]   PAOLO GUIDETTI ET AL: "In Situ Produced 7-Chlorokynurenate Provides Protection against Quinolinate- and Malonate-Induced Neurotoxicity in the Rat Striatum", EXPERIMENTAL NEUROLOGY, vol. 163, no. 1, 1 May 2000 (2000-05-01), US, pages 123 - 130, XP055283120, ISSN: 0014-4886, DOI: 10.1006/exnr.1999.7284

DOI:   http://dx.doi.org/10.1006/exnr.1999.7284
 [A]   LINDERHOLM ET AL: "Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: A pharmacological analysis", NEUROPHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 53, no. 8, 22 November 2007 (2007-11-22), pages 918 - 924, XP022358184, ISSN: 0028-3908, DOI: 10.1016/J.NEUROPHARM.2007.09.003

DOI:   http://dx.doi.org/10.1016/j.neuropharm.2007.09.003
 [A]   HUI-QIU WU ET AL: "Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 319, no. 1, 1 January 1997 (1997-01-01), NL, pages 13 - 20, XP055283118, ISSN: 0014-2999, DOI: 10.1016/S0014-2999(96)00829-1

DOI:   http://dx.doi.org/10.1016/S0014-2999(96)00829-1
 [T]   P. ZANOS ET AL: "The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 355, no. 1, 11 August 2015 (2015-08-11), pages 76 - 85, XP055283128, DOI: 10.1124/jpet.115.225664

DOI:   http://dx.doi.org/10.1124/jpet.115.225664
by applicantUS5547991
   SALITURO ET AL.: "Enzyme-Activated Antagonists of the Strychnine-Insensitive Glycine/NMDA Receptor", J. MED. CHEM., vol. 37, 1994, pages 334,336
   TAMBASCO, N. ET AL.: "Clinical Aspects and Management of Levodopa-Induces Dyskinesia", PARKINSON'S DISEASE, 2012
   CALABRESE ET AL.: "Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment", PLOS ONE, vol. 7, no. 5, 2012, pages E37916
   CARTER AJ: "Glycine antagonist: Regulation of the NMDA receptor channel complex by the strychnine-insensitive glycine site", DRUGS FUTURE, vol. 17, 1992, pages 595 - 613
   CATARZI ET AL.: "Competitive Gly/NMDA receptor antagonists", CURR. TOP. MED. CHEM., vol. 6, no. 8, 2006, pages 809 - 821
   HOKARI M; WU H-Q; SCHWARCZ R; SMITH QR: "Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid", NEUROREPORT, vol. 8, no. 1, 1996, pages 15 - 18
   KEMP JA ET AL.: "7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex", PROC NATL ACADS SCI U.S.A., vol. 85, no. 17, 1988, pages 6547 - 6550
   LEE S-C; SCHWARCZ R: "Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo", NEUROSCIENCE LETT, vol. 304, no. 3, 2001, pages 185 - 188
   LEESON PD; IVERSEN LL: "The glycine site on the NMDA receptor: Structure-activity relationships and therapeutic potential", J MED CHEM, vol. 37, no. 24, 1994, pages 4053 - 4067
   LINDERHOLM ET AL.: "Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis", NEUROPHARMACOLOGY, vol. 53, no. 8, 2007, pages 918 - 924
   PARSONS CG ET AL.: "Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization", J PHARMACOL EXP THER, vol. 283, no. 3, 1997, pages 1264 - 1275
   RAO TS; GRAY NM; DAPPEN MS; CLER JA; MICK SJ; EMMETT MR ET AL.: "Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: in vivo characterization", NEUROPHARMACOL, vol. 32, no. 2, 1993, pages 139 - 147
   RUNDFELDT C; WLAZ P; LOSCHER W: "Anticonvulsant activity of antagonists and partial agonists for the NMDA receptor-associated glycine site in the kindling model of epilepsy", BRAIN RES, vol. 653, no. 1-2, 1994, pages 125 - 130
   WU HQ; LEE SC; SCHARFMAN HE; SCHWARCZ R: "L-4-chlorokynurenine attenuates kainate-induced seizures and lesions in the rat", EXP NEUROL, vol. 177, no. 1, 2002, pages 222 - 232
   WU H-Q; LEE S-C; SCHWARCZ R: "Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus", EUR J PHARM, vol. 390, 2000, pages 267 - 274
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.